PharmaBoardroom

Lance Little – Managing Director (Asia Pacific), Roche…

Lance Little, managing director for Roche Diagnostics in Asia Pacific and board member of the Asia Pacific Medical Technology Association (APACMed),…

The Collaborative Spirit of Cell & Gene

One of the more intriguing aspects about the new wave of cell and gene therapies (CGT) coming onstream is that they are not just technologically…

Maria T Millan – President & CEO, California Institute…

Dr Maria T. Millan, president and CEO of the California Institute for Regenerative Medicine (CIRM), shares the Institute’s mission to advance basic…

5 European Rare Disease Start-Ups to Watch

With Rare Disease Day falling on 28 February, PharmaBoardroom dedicates this month to exploring the global rare disease landscape, highlighting key…

Reconsidering Cell & Gene Therapy Manufacturing

Advances in cell and gene therapies (CGT) are credited with thoroughly transforming medicinal science and creating an inflection point in the ability…

Curing the Incurable: Cell & Gene Therapy and A New Age for…

Bayer’s Michael Levy casts his eye over the implications of the advent of cell and gene therapies on pharmacovigilance and patient safety. Levy…

Funding the Cell & Gene Therapy Boom

The ascent of cell and gene therapies (CGT) is commonly regarded as one of the momentous turning points in the history of the pharmaceuticals…

RWE: Unlocking the Full Potential of Cell & Gene

Emerging cell and gene therapies herald immense clinical value for patients, society, and healthcare systems: carrying the potential to offer…

Navigating the Increasingly Stormy Waters of US Market Access

Certara's Ulrich Neumann examines some of the major US market access trends of the past few years, including the innovative financing models required…